Fluoroquinolone Photodegradation Influences Specific Basophil Activation
Quinolones have been used for more than 30 years to treat a wide range of infections. UV radiation induces their photodegradation, which is modulated by the nature and position of the substituents attached to the quinolone skeleton [1, 2] . For example, the presence of a halogen, as in fluoroquinolones (FQs), seems to be associated with a higher phototoxic potential [3, 4] . Photodecomposition may involve a variety of photochemical processes, such as generation of singlet oxygen, production of superoxide, defluorination, decarboxylation at C-3, or oxidation of the amino group at C-7 [1, 2, 4] .
Generally FQs are well tolerated [5] , although the last decade has witnessed an increasing number of immediate hypersensitivity reactions (IHR) induced by FQs, with urticaria and anaphylaxis being the most frequently reported reactions [6] [7] [8] . These observations, especially the occurrence of more severe reactions, have been associated with the introduction of moxifloxacin (MOX) for therapeutic use [6] . In fact, in a group of patients diagnosed with IHR to FQs, MOX was involved in more than 60% of the cases with more severe reactions, followed by ciprofloxacin (CIP) in 30% and, to a much lower extent, levofloxacin [8] .
Evidence supporting an immunoglobulin E (IgE) mechanism for IHR has been provided by the detection of specific antibodies, by both immunoassay and basophil activation tests (BAT), with different patterns of cross-reactivity among FQs [7, 8] . Despite these findings, the true nature of the haptenic substructure (from the parent drug or its metabolites) recognized by the immune system remains unknown. The BAT is an adequate model for studying IgE-mediated reactions to FQs because, in addition to sensitized basophils, it enables study of the hapten, both free and protein bound, as well as its metabolites.
Previous evidence from well-validated CIP and MOX IHR cases suggests that basophil activation occurs with CIP more often than with MOX, even in those cases where MOX was the culprit drug [8] . Because each FQ exhibits chemical differences, our hypothesis was that they may behave differently upon light exposure, which may influence the formation of drug-protein conjugates and therefore interfere with the basophil activation. To test this hypothesis, we investigated how light exposure can affect the BAT results in patients with IgE-mediated hypersensitivity reactions and controls with good tolerance to these FQs.
Material and Methods
The stability of the FQs when exposed to laboratory light was checked by spectrophotometric and fluorometric measurements in an aqueous solution and in supernatants obtained from the BAT. These supernatants were divided into high molecular weight fractions ( 1 3,000 Da), containing the drug bound to the serum proteins, and low molecular weight fractions ( ! 3,000 Da), with the free drug or its metabolites, before analysis.
The BAT was done as described [8] under light and dark conditions with whole blood from patients with confirmed immediate hypersensitivity to CIP (n = 15) or MOX (n = 13) and quinolone-tolerant controls (n = 20). Results were considered positive when the stimulation index (SI), calculated as the ratio between the percentage of degranulated basophils with the haptens and the spontaneous basophil activation, was greater than 3. Detailed information about the photochemical and biological studies is available in the online supplementary material (for all online suppl. material, see www.karger.com/doi/10.1159/000343023).
Results

Photostability of CIP and MOX
Absorption spectra of CIP and MOX showed a wide wavelength band reaching up to 400 nm (online suppl. fig. S1A and online suppl. material). Emission studies were performed by excitation at 320 and 337 nm for CIP and MOX, respectively, displaying different emission bands centered at 420 nm for CIP and 460 nm for MOX. Neither CIP nor MOX exhibited significant spectroscopic changes under light or dark conditions in aqueous solution, indicating a low photodegradation (online suppl. fig. S1B ).
We then analyzed the effect of laboratory light on FQ degradation and on their capability to form drug-protein conjugates in whole blood, the medium used in BAT. The emission data of the low and high molecular weight fractions showed few, if any, differences in fluorescence intensity for CIP under light or dark conditions, either in free or protein fractions ( fig. 1 ). However, remarkable differences were observed for MOX in both fractions, with an important decrease in fluorescence emission intensity upon light exposure, indicating drug photodegradation.
BAT Results
Twenty-eight patients with confirmed IHR to CIP and MOX and 20 controls with confirmed good tolerance to FQs were evaluated ( table 1 and online suppl. material). Figure 2 shows the dose-response curve with four different concentrations of CIP and MOX, in light and dark conditions, in 16 allergic patients and 15 controls. The optimal concentrations were found to be 0.2 and 2 mg/ml for both drugs, and these concentrations were used throughout the study. Table 1 shows the results of the BAT for CIP and MOX in light and dark conditions for the individual cases. For CIP, BAT was positive in 13 cases (46.4%) under light conditions and in 13 cases (46.4%) under dark conditions. For MOX, BAT was positive in 5 cases (17.9%) under light conditions and in 10 cases (35.7%) under dark conditions. Results were positive to either of the two FQs in 13 cases (46.4%) under light conditions and in 16 cases (57.1%) under dark conditions. Online supplementary figure S2 shows the dot plot in light and dark conditions of two representative cases.
Analysis of the results depending on the FQ involved in the reaction showed that, in those cases where CIP was the culprit drug (n = 15), BAT was positive to CIP in 5 cases (33.33%) in light and 6 cases (40%) in dark conditions, to MOX in 6 cases (40%) in light and 4 cases (26.66%) in dark conditions, and to either of the two quinolones in 5 cases (33.33%) in light and 8 cases (53.33%) in dark conditions.
In those cases where MOX was the culprit drug (n = 13), BAT was positive to CIP in 8 cases (61.53%) in light and 7 cases (53.84%) in dark conditions, to MOX in 2 cases (15.38%) in light and 6 cases (46.15%) in dark condi- tions, and to either of the two FQs in 8 cases (61.53%) in both light and dark conditions.
In controls (n = 20), under light conditions, BAT was positive in 2 cases to CIP, in 1 case to MOX, and in 2 cases to at least one FQ; in dark conditions, BAT was positive in 1 case to CIP, in 2 cases to MOX, and in 2 cases to at least one FQ. As a result, the specificity was 90% in both light and dark conditions.
Discussion
The presence of IgE antibodies to FQs has been demonstrated by immunoassays, including inhibition studies, although they do not enable us to determine the hapten determinant involved [7, 8] . Recently, BAT has proven to be a useful tool for evaluating IgE responses to these drugs, though the results seem to depend on the FQ used in the test and are lower with MOX [8] . This, together with the fact that in recent years there has been an increase in the number of MOX reactions (in most cases severe), [6, 8] makes it important to analyze in depth the factors influencing these different behaviors. Based on the photolability of FQs [1-3, 9] our hypothesis was that the differences found in the BAT assay between the FQs may be explained by changes induced under light exposure during the in vitro test procedure, which influences FQ degradation differently, producing a lower amount of drug-protein conjugates. The results obtained from fluorescence emission studies suggest that during BAT both FQs are able to bind to blood proteins, although free drug also remains. The data show an important photodegradation under laboratory light conditions, especially for MOX; as a consequence, lower drug-protein conjugates are also obtained. These results could be explained in terms of photostability since both FQs, although they present the same basic structure, show a different photochemical behavior due to different substituents [1, 2] . Even though the presence of a fluorine atom in C-6 makes both drugs somewhat photoreactive, the degree to which the molecules are photolabile is modulated by substituents and is directly related to the electronegativity of the substituent at C-8 [3, 4] . When we analyzed the photostability in aqueous solution we observed a similar behavior for both FQs. However, important differences, with a high MOX degradation, were found when the same experiments were done in whole blood, mimicking the BAT conditions. This may be explained by the fact that the photochemical behavior also depends on the characteristics of the medium, particularly in biological environments [1, 2] . Thus, in this study the complexity of the blood samples showed the unexpected facet of the reactivity of these FQs, which makes it difficult to formulate a hypothesis about the mechanisms involved.
These data explain why BAT positivity under light exposure was lower with MOX (17.9%) than with CIP (46.4%), with no patients being positive solely to MOX, as previously reported [8] . However, when the BAT results were analyzed under dark conditions, there was an increase in the number of positive cases to at least one FQ, from 46.4 to 57.1%.
The results obtained in BAT with the lower response observed with MOX in light (17.9%) compared to dark (35.7%) conditions and no changes in positivity for CIP (46.4%) correlate with the different photobehavior observed in these FQs, with degradation after light stimulation found only in MOX. Thus, in order to improve the sensitivity of BAT with MOX, this assay should be carried out under dark conditions to avoid drug photodegradation and possible misleading results.
Analysis of the results depending on the culprit drug showed that in patients in whom MOX was responsible, in light conditions only 15.38% were BAT positive to this drug while 61.53% were positive to CIP. Thus, although the culprit drug was MOX, most cases were positive to CIP, as in the study by Aranda et al. [8] . This phenomenon was not detected when CIP was the culprit drug. The reason for this was that all of the cases that were positive to MOX were also positive to CIP, indicating that although the reaction was induced by MOX, IgE recognition was in part directed to CIP. Similar results have been published for patients with IHR to amoxicillin or amoxicillin-clavulanic acid where IgE mainly recognized benzylpenicillin [10, 11] . This seems to indicate that IgE antibodies are related to the drug of first exposure (benzylpenicillin and CIP), even if no previous reaction occurred, thus reflecting an anamnestic immune response [10, 11] . The occurrence of this phenomenon is expected to decrease over time as MOX consumption increases compared to CIP, as demonstrated with betalactams where benzylpenicillin is no longer the structure most often recognized [11, 12] .
Finally, the question remains of whether the lower sensitivity for MOX found in BAT could also affect other in vitro tests, such as the radioimmunoassay. This may be the case since a lower sensitivity was found with sepharose-RIA to MOX (18%) compared to that achieved with CIP (21%) in the study by Aranda et al. [8] , although further research is needed to analyze whether this phenomenon may influence other in vivo or in vitro tests.
Summarizing, the data reported here suggest that MOX is sensitive to ambient laboratory light present during the performance of an in vitro assay such as BAT, producing higher drug photodegradation and, as a consequence, lower amounts of drug-protein conjugates. This shows that light exposure is a critical factor in the results of the BAT when photolabile drugs are used and it is important to bear this in mind when interpreting in vitro results.
